You can read the full February 6th print issue of Chain Drug Review in its entirety here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
WARREN, N.J. — The worst of this year’s cough/cold season may be over for some people, but consumers should still be wary of respiratory ailments for the remainder of winter. “We have seen an early and intense ramp-up of flu, RSV, colds and new COVID-19 variants. Consumers may have already experienced the impact of winter
Today’s most compelling, and alarming, trend in sexual wellness is the secondary thought given to condom use among Millennial and Gen Z adults. According to both IRI and Nielsen, condom sales at brick-and-mortar have tracked slightly downward or leveled over the last several quarters and years. We know much purchasing has gone to online marketplaces,
FRANKLIN, Tenn. — Today, companies need to adapt and be more agile than ever. That’s especially true for businesses across all levels of the chain drug store retail landscape, which extends from retail and pharmacy to public health services. Trey Holder, accelerate360’s chief business officer and president of distribution and logistics, recently had the opportunity
It usually happens when women are in their 40s, but sometimes earlier. Suddenly, a monthly cycle that was predictable becomes erratic. Fluctuating hormones begin to impact aspects of daily life, from sleep to relationships to bladder changes. It’s called perimenopause, and for too long it’s been overlooked in women’s health care. Perimenopause happens before menopause,
By now it has become a familiar refrain: Amazon is taking another step to extend its reach in the $4 trillion health care sector. Late last month [January], the company launched RxPass, a benefit that gives Amazon Prime members access to some 50 generic medications, used to treat 80 common health problems, for a flat
The new year has been under way for about a month now, and speculation about the upcoming 12 months already abounds. Not to be left at the starting gate, here’s a look from Chain Drug Review’s headquarters into what just might happen between now and December 31 and what will remain anyone’s guess. To begin,
